RegeneMed Says 3D Liver Tissue Surrogate Is Physiologically Relevant ADME/Tox Model | GenomeWeb
ANAHEIM, Calif. - Tissue engineering shop RegeneMed has developed a 3D liver tissue surrogate for ADME/Tox testing that can offer pharmaceutical companies long-term predictive cell life and human functionality, according to a company official.       
 
Dawn Applegate, president and CEO of RegeneMed, discussed the Carlsbad, Calif.-based company’s hepatic model, which it launched in June, at the Society for Biomolecular Sciences’ Stem Cells and Primary Cells in Drug Discovery symposium, held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.